CRT is the standard of care for patients with unresectable stage III LA-NSCLC, most patients relapse. Tecemotide is a MUC1 antigen-specific cancer immunotherapy vaccine. Bevacizumab improves survival in advanced NS-NSCLC and has a role in immune modulation. This phase II trial tested the combination of tecemotide and bevacizumab following CRT in patients with LA-NSCLC.

70 were enrolled for the study purpose. Out of those 70 patients, only 68 patients initiated therapy, but only 39 patients completed CRT and consolidation therapy per protocol, primarily owing to disease progression or toxicity. Thirty-three patients were registered to step 2. Among the 32 treated and the eligible patients who were treated on step 2, the median overall survival was 42.7 months, and the median progression-free survival was 14.9 months from step 1 registration.


This study concluded by demonstrating tolerability of bevacizumab + tecemotide after CRT and consolidation. In this selected group of patients, the median progression-free survival and overall survival are encouraging. Given that consolidation immunotherapy is now a standard of care following CRT in patients with LA-NSCLC, these results support a role for continued investigation of antiangiogenic and immunotherapy combinations in LA-NSCLC.